Market Update: Growth And Opportunities In Peripheral Artery Disease
Drug-coated balloon (DCBs) catheters have become the latest weapon in the fight against peripheral artery disease in the US, although they have been in use in Europe for some time. While the number of procedures employing DCBs is still dwarfed by conventional angioplasty procedures, they are expected to grow at a much faster rate, fueling a market projected to reach $1 billion by 2020; meanwhile other procedures such as mechanical atherectomy are also expected to show significant growth.
You may also be interested in...
SurModics Recruits Abbott To Commercialize SurVeil Drug-Coated Balloon
Abbott will pay SurModics $25m upfront and up to $67m in milestones for the exclusive right to commercialization SurVeil worldwide.
Starts & Stops: New Trial Starts Led By Peripheral Vascular Interventions
Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions the past month or so. Over the last month, 38 new trials started, 17 trial were completed, one trial was "reinitiated," and four trials were terminated or suspended, according to Meddevicetracker.
OUS Approvals Analysis: Medtronic, Abbott, Abionic Lead 2017 Upswing
The 20 non-US medical device approvals in January, including eight in in vitro diagnostics, four in orthopedics, and three in cardiovascular devices. Big medtech players Medtronic and Abbott, accompanied by much smaller Swiss IVD firm Abionic, led the charge and bagged more OUS approvals than most.